In late 2023, she received a diagnosis of High Grade Adenocarcinoma Lung Cancer, with a tumor measuring an alarming 11 cm. Initially, her doctor prescribed targeted chemotherapy to address the rapidly growing tumor. However, as the tumor continued to progress despite treatment, her doctor suggested incorporating ECCT into her treatment plan as a complementary therapy to the chemotherapy regimen.
在2023年底，她被诊断为高等级肺腺癌，肿瘤大小达到令人担忧的11厘米。起初，她的医生开出了靶向化疗药物来应对迅速增长的肿瘤。然而，尽管接受了治疗，肿瘤依然持续进展，因此医生建议将ECCT作为补充治疗纳入她的治疗方案。The results were remarkable. Within just one month of using ECCT alongside her prescribed chemotherapy, 80% of the tumor mass had disappeared. This significant reduction in tumor size marked a major turning point in her treatment journey. The remaining tumor mass, which is anticipated to transition into fibrosis (scar tissue), is considered relatively stable and typically does not require further intervention.
结果令人震惊。在仅仅一个月的时间里，结合使用ECCT和化疗后，肿瘤质量减少了80%。这一显著的肿瘤缩小标志着她治疗过程中的一个重要转折点。剩余的肿瘤质量预计会转变为纤维化（瘢痕组织），通常不再需要进一步的治疗。Thanks to the combined approach of ECCT and chemotherapy, she has achieved a level of health and well-being that allows her to live a normal, active life once again. Her story stands as a testament to the potential of innovative treatment combinations in addressing high-grade cancers and restoring quality of life.
得益于ECCT和化疗的联合治疗，她恢复了健康，重新过上了正常且积极的生活。她的故事见证了创新治疗组合在应对高等级癌症和恢复生活质量方面的巨大潜力。
Comments